Eli Lilly (NYSE: LLY) has settled a dispute regarding the Cialis (tadalafil) unit dose patent.
The company has agreed with generics drugmakers that the patent, which was previously set to expire in April 2020, will now end at the earliest in September next year.
Senior VP and general counsel Michael Harrington said: "The unit dose patent for Cialis is valid and infringed by companies seeking to market a generic version of Cialis.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze